Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
31.20 x 1 34.10 x 1
Pre-market by (Cboe BZX)
31.20 +3.16 (+11.27%) 04/11/25 [NASDAQ]
31.20 x 1 34.10 x 1
Pre-market 31.20 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
27.80
Day High
31.31
Open 27.97
Previous Close 28.04 28.04
Volume 4,052,600 4,052,600
Avg Vol 3,486,295 3,486,295
Stochastic %K 4.87% 4.87%
Weighted Alpha -40.45 -40.45
5-Day Change -0.40 (-1.27%) -0.40 (-1.27%)
52-Week Range 27.66 - 121.06 27.66 - 121.06
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,017,375
  • Shares Outstanding, K 128,762
  • Annual Sales, $ 0 K
  • Annual Income, $ -463,930 K
  • EBIT $ -570 M
  • EBITDA $ -592 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06

Options Overview Details

View History
  • Implied Volatility 76.21% ( -17.14%)
  • Historical Volatility 189.07%
  • IV Percentile 73%
  • IV Rank 43.68%
  • IV High 135.29% on 08/06/24
  • IV Low 30.38% on 09/24/24
  • Put/Call Vol Ratio 0.32
  • Today's Volume 229
  • Volume Avg (30-Day) 1,042
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 15,979
  • Open Int (30-Day) 11,743

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.02
  • Number of Estimates 3
  • High Estimate -0.85
  • Low Estimate -1.15
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.66 +12.80%
on 04/10/25
Period Open: 69.85
76.61 -59.27%
on 03/21/25
-38.65 (-55.33%)
since 03/11/25
3-Month
27.66 +12.80%
on 04/10/25
Period Open: 81.08
93.77 -66.73%
on 01/28/25
-49.88 (-61.52%)
since 01/10/25
52-Week
27.66 +12.80%
on 04/10/25
Period Open: 64.83
121.06 -74.23%
on 09/19/24
-33.63 (-51.87%)
since 04/11/24

Most Recent Stories

More News
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

PCVX : 31.20 (+11.27%)
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

PCVX : 31.20 (+11.27%)
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst

Last November, Fundstrat analyst Tom Lee told CNBC that small-cap stocks are headed for a prolonged period of outperformance compared to the large-cap S&P 500 (SNPINDEX: ^GSPC) . "I think small caps could,...

PCVX : 31.20 (+11.27%)
SSB : 81.45 (-0.12%)
$SPX : 5,363.36 (+1.81%)
FTAI : 98.92 (+2.58%)
MORN : 273.35 (+0.98%)
SFM : 157.27 (+2.18%)
GS : 494.44 (+0.95%)
INSM : 68.57 (+5.80%)
VTWO : 74.47 (+1.44%)
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PCVX : 31.20 (+11.27%)
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

PCVX : 31.20 (+11.27%)
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

PCVX : 31.20 (+11.27%)
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine (PCV),...

PCVX : 31.20 (+11.27%)
MRK : 79.18 (+2.10%)
PFE : 21.91 (+1.48%)
SNY : 51.50 (+3.71%)
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

PCVX : 31.20 (+11.27%)
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating invasive...

PCVX : 31.20 (+11.27%)
MRK : 79.18 (+2.10%)
PFE : 21.91 (+1.48%)
SNY : 51.50 (+3.71%)
New Vaccine Technologies Lead the Charge as Global Immunization Efforts Evolve

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – According to the World Health...

PCVX : 31.20 (+11.27%)
BVAXF : 0.0397 (-0.25%)
BIOV.CN : 0.0500 (unch)
GILD : 103.63 (+2.20%)
GOVX : 1.0200 (+7.31%)
ARCT : 9.70 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 35.92
2nd Resistance Point 33.61
1st Resistance Point 32.41
Last Price 31.20
1st Support Level 28.90
2nd Support Level 26.59
3rd Support Level 25.39

See More

52-Week High 121.06
Fibonacci 61.8% 85.38
Fibonacci 50% 74.36
Fibonacci 38.2% 63.34
Last Price 31.20
52-Week Low 27.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar